Novo Nordisk A/S: EPS $0.89 vs $0.731 expected; revenue $11.9B vs $11.1B
Key Facts
Q3 FY2026 results
| Metric | Actual | Estimate | Surprise | Year ago |
|---|---|---|---|---|
| EPS (USD) | 0.890 | 0.731 | +21.8% | 1.020 |
| Revenue (USD bn) | 11.860 | 11.070 | +7.2% | 11.530 |
Recent reports: actual vs estimate
| Reported | Period | EPS (USD) | Estimate | Surprise | Revenue (USD bn) | Estimate | Surprise |
|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | Q3 FY2026 | 0.89 | 0.731 | +21.8% | 11.86 | 11.07 | +7.2% |
| Aug 5, 2026 | Q2 FY2026 | 0.96 | 0.820 | +17.1% | 12.13 | — | — |
| May 6, 2026 | Q1 FY2026 | 1.04 | 0.870 | +19.5% | 11.02 | 10.86 | +1.5% |
| Feb 3, 2026 | Q4 FY2025 | 1.00 | 0.900 | +11.1% | 12.50 | 12.13 | +3.1% |
| Nov 5, 2025 | Q3 FY2025 | 1.02 | 0.770 | +32.5% | 11.53 | 11.94 | −3.5% |
| Aug 6, 2025 | Q2 FY2025 | 0.97 | 0.930 | +4.3% | 11.97 | 11.92 | +0.4% |
| May 7, 2025 | Q1 FY2025 | 0.92 | 0.920 | 0.0% | 11.90 | 11.70 | +1.7% |
| Feb 5, 2025 | Q4 FY2024 | 0.91 | 0.880 | +3.4% | 11.86 | 11.55 | +2.7% |
Source: Figures from the EL7 database. Estimates are the analyst consensus carried by our data vendor (FMP), not official figures. Figures are in USD as carried for this US-traded line; the company reports in another currency.
Novo Nordisk A/S results: EPS $0.89 vs $0.731 expected; revenue $11.9B vs $11.1B. The results cover the company's Q3 FY2026. EPS came in above analysts' estimate by 21.8%; revenue above the estimate by 7.2%. Figures are in USD as carried for this US-traded line; the company reports in DKK.
Revenue was up 2.9% from $11.5 billion a year earlier (Q3 FY2025). EPS was down 12.7% from $1.02 a year earlier. On its record, EPS topped analysts' estimates in 6 of 7 earlier comparable reports.
What the results mean
Novo Nordisk’s business centers on diabetes and obesity treatments, alongside therapies for rare diseases. Its business drivers are tied to the adoption of these treatments and its ability to develop, manufacture and distribute medicines across its international markets.
Medicines are complemented by delivery devices and digital diabetes management solutions, extending the company’s activities from treatment to supporting its use. Therapies for rare blood and endocrine disorders provide a distinct business stream, while research partnerships support drug development for cardiometabolic diseases.
What to watch on the earnings call: Demand for diabetes and obesity treatments across markets, manufacturing and distribution capacity to serve that demand, the role of rare disease therapies in the business mix, research and partnership progress in cardiometabolic diseases, and the contribution of injection devices and digital solutions to supporting treatment use.
For the full analysis of Novo Nordisk A/S stock — valuation, scores and financial statements — see the stock page linked with this story.